|
| Press Releases |
|
 |
|
| Monday, June 11, 2018 |
|
|
AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA |
| The newly launched pen-type auto-injector devices were developed to simplify the operation and reduce the burden on patients when performing self-injection. more info >> |
|
| Wednesday, June 6, 2018 |
|
|
Eisai: Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting |
| Eisai Co., Ltd. and Purdue Pharma L.P. presented the results of two key Phase I clinical studies (Study 108 and Study 106) of their investigational sleep/wake regulation agent lemborexant at the 32nd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2018), from June 2 to 6 in Baltimore, Maryland, the United States. more info >> |
|
| Tuesday, June 5, 2018 |
|
|
Eisai: PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months |
| Eisai Co., Ltd. and Biogen Inc. announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (AB) levels in the brain measured by amyloid-PET (positron emission tomography). more info >> |
|
| Monday, June 4, 2018 |
|
|
Eisai and Merck Announce Data at 2018 ASCO Annual Meeting |
| The data are included in presentations at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5. LENVIMA and KEYTRUDA are not approved for use in combination in any cancer types today. more info >> |
|
| Thursday, May 31, 2018 |
|
|
U.S. FDA Designates for Priority Review of Eisai's Supplemental New Drug Application for Antiepileptic Drug Fycoma |
| Eisai Co., Ltd. has announced the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Eisai's antiepileptic drug (AED) Fycompa (perampanel). more info >> |
|
| Monday, May 28, 2018 |
|
|
Eisai: PIII Clinical Study Data on Chronic Constipation Treatment "GOOFICE 5mg Tablet" will be Presented at DDW2018 |
| Eisai Co., Ltd., Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. announce that an oral presentation on PIII clinical study data on "GOOFICE 5mg Tablet". more info >> |
|
| Friday, May 25, 2018 |
|
|
Eisai: Potent New Mechanism of Action for Treatment of Inflammatory Bowel Disease |
| This novel mechanism of action elucidated is expected to lead to value enhancement and acceleration of the development of E6007 which aims to provide a new remedy for IBD patients. more info >> |
|
|
Eisai and Merck & Co. Provide Update on Supplemental New Drug Application (sNDA) for Lenvatinib |
| The FDA has indicated that the extension of the Prescription Drug User Fee Act (PDUFA) date is needed to allow additional time for review of the application. more info >> |
|
| Wednesday, May 23, 2018 |
|
|
Eisai and Purdue Pharma to Present Latest Phase I Clinical Data on Lemborexant at 32nd Annual Sleep Meeting |
| Eisai Co., Ltd. and Purdue Pharma L.P. today announced they will present the latest data from two key Phase I clinical studies (Study 108 and Study 106). more info >> |
|
| Thursday, May 17, 2018 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered multiple receptor tyrosine kinase inhibitor lenvatinib mesylate will be presented during the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 1 to 5, 2018. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Michael Owen Becomes the New Face of GK8: Fastest Growing iGaming Brand 
Aug 3, 2025 13:00 HKT/SGT
|
|
|
Risetcar's driverless taxis are performing well in the US, with Jakarta operations set to launch soon
Aug 2, 2025 21:30 HKT/SGT
|
|
|
Kuvi.ai Launches Private Beta of Agentic Finance OS with Seed Round Led by Moon Pursuit Capital
Aug 2, 2025 11:30 HKT/SGT
|
|
|
Rust Mobile Revealed With Official Trailer, First Hands-on Demo Set for Gamescom 2025
Aug 2, 2025 00:30 HKT/SGT
|
|
|
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Aug 2, 2025 00:02 HKT/SGT
|
|
|
TSE Group Launches Papua's First POME-to-Energy Plant
Aug 1, 2025 23:00 HKT/SGT
|
|
|
Concord New Energy (0182.HK) Released 2025 Interim Results
Aug 1, 2025 21:49 HKT/SGT
|
|
|
Queensland's Stralis lands clean aviation breakthrough in Japan, announced at Expo 2025 Osaka
Aug 1, 2025 20:00 JST
|
|
|
Queensland leads global education charge at Expo 2025 Osaka
Aug 1, 2025 20:00 JST
|
|
|
Hitachi completes capital reorganization of air conditioning joint venture accelerating the deployment of green cooling solutions through "One Hitachi"
Aug 1, 2025 19:00 JST
|
|
|
Naoris Protocol Stakes $120,000 Bounty To Break Cryptography Securing $470 Trillion Global Economy
Aug 1, 2025 16:50 HKT/SGT
|
|
|
Mitsubishi Motors and Security Bank launch Mitsubishi Motors Finance Philippines Inc.
Aug 1, 2025 17:00 JST
|
|
|
Honda Turkiye A.S. decided to establish Motorcycle Production Factory
Aug 1, 2025 16:45 JST
|
|
|
Global Property Expo | Singapore 2025 attracts 2,500 Buyers With Intent, 40+ Exhibitors, with Projects spanning 20 Countries
Aug 1, 2025 14:48 HKT/SGT
|
|
|
Honda Begins Joint Demonstration of Stationary Fuel Cell Power Station Designed to Utilize By-product Hydrogen and Repurposed Automotive Fuel Cells
Aug 1, 2025 11:20 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
